Teleflex (NYSE:TFX) Issues Quarterly Earnings Results

Teleflex (NYSE:TFX) announced its quarterly earnings data on Thursday. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80), FiscalAI reports. The company had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $912.57 million. Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. The company’s quarterly revenue was down 28.5% compared to the same quarter last year. During the same period last year, the business earned $3.89 earnings per share. Teleflex updated its FY 2026 guidance to 6.250-6.550 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Teleflex signed definitive agreements to sell its Acute Care, Interventional Urology, and OEM businesses for total cash proceeds of $2.03 billion (approximately $1.8 billion after tax), expected to close in H2 2026, and intends to use proceeds to repurchase up to $1 billion of shares and pay down roughly $800 million of debt.
• 2026 adjusted EPS guidance of $6.25–$6.55 incorporates a full-year drag from an estimated $90 million of stranded costs and excludes positive effects from TSAs/MSAs and planned share repurchases, making 2026 a transition year before expected EPS improvement in 2027.
• Management approved a restructuring to rightsize the organization and mitigate stranded costs, targeting about $50 million in annual pre-tax savings (substantially completed by mid-2028) with some savings already included in 2026 guidance.
• The newly defined RemainCo will focus on Vascular, Interventional, and Surgical portfolios and plans to increase R&D to about 8% of sales (vs ~5% historically) to accelerate product innovation and long-term growth.
• Continuing operations showed pro forma adjusted constant-currency revenue growth of 4.7% in H2 2025 (Interventional +8.1%), 2025 adjusted EPS was $6.98 (+8.7% YoY), and the BIOTRONIK Vascular Intervention acquisition integration is progressing with anticipated salesforce and revenue synergies.

Teleflex Trading Up 2.5%

TFX stock traded up $2.93 during midday trading on Friday, reaching $121.95. 1,693,141 shares of the company traded hands, compared to its average volume of 1,086,067. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -16.59, a P/E/G ratio of 1.46 and a beta of 0.92. Teleflex has a 52-week low of $100.18 and a 52-week high of $143.32. The business has a 50 day moving average of $111.34 and a 200-day moving average of $118.68. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 2.57.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th will be given a dividend of $0.34 per share. The ex-dividend date is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex’s dividend payout ratio is -18.50%.

Institutional Trading of Teleflex

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UMB Bank n.a. boosted its stake in shares of Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares during the period. Maryland State Retirement & Pension System raised its stake in Teleflex by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after acquiring an additional 129 shares during the last quarter. Osaic Holdings Inc. lifted its position in Teleflex by 17.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock worth $148,000 after acquiring an additional 186 shares during the period. Vident Advisory LLC grew its stake in shares of Teleflex by 2.8% in the 4th quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock valued at $853,000 after purchasing an additional 188 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in shares of Teleflex by 15.8% in the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after purchasing an additional 230 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wells Fargo raised its price target to $130 (from $116) and maintained an “equal weight” rating — a near-term bullish signal that can support buying interest. Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $125 (from $115) with a “sector perform” rating — another analyst lift that helps underpin the rally. Read More.
• Positive Sentiment: Teleflex’s board declared a quarterly cash dividend of $0.34 per share (record date March 6, payable March 31), which can attract income-seeking investors and provide support. Read More.
• Positive Sentiment: The company launched a multi?year restructuring tied to planned divestitures — investors appear to view this as steps to simplify the portfolio, cut costs and potentially unlock value. Read More.
• Neutral Sentiment: Teleflex published its Q4 presentation and full-year results (material and earnings?call transcripts are available) — useful for modeling but not a driver by itself. Read More.
• Negative Sentiment: Q4 results missed materially: EPS $1.93 vs. consensus ~$3.73 and revenue $569M vs. ~$912.6M — revenue fell ~28.5% year-over-year and margins contracted, a clear near-term negative for earnings momentum. Read More.
• Negative Sentiment: FY?2026 guidance was significantly reduced: EPS guidance of $6.25–$6.55 and revenue guidance around $2.3B vs. street expectations materially higher (~$15 EPS and ~$3.7B revenue), which is a major downward re?rating of near-term expectations. Read More.

Analyst Ratings Changes

Several equities analysts recently weighed in on TFX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Truist Financial raised their price objective on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Wall Street Zen downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Wells Fargo & Company raised their price target on Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a report on Friday. Finally, Needham & Company LLC lifted their price objective on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $140.63.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.